We are interested in a high-throughput screening assay of a variety of drugs with known pharmacological impacts and their effects on reducing stress-induced-sleep (SIS) in C. elegans. We hope that these findings will not only help us elucidate novel mechanisms of stress-induced-sleep, but also pave the way for further research and treatment options for those with disorders such as insomnia or chronic fatigue syndrome. We are working with the High Throughput Screening Core Facility, headed by Dr. David Schultz and are screening through around 4000 drugs, around 1500 of which are FDA approved drugs and 2000 have known pharmacological effects.